

ABSTRACT

There is disclosed an application of a traditional Chinese medicine composition in preparation of medicament for preventing and treating coronavirus infection combined with lung damage. The present disclosure has screened traditional Chinese medicine compositions for an
5 intervening effect on the novel coronavirus (SARS-CoV-2). The results of the clinical trial show that the disclosed traditional Chinese medicine composition is very capable of inhibiting lung damage and pulmonary fibrosis caused by the novel coronavirus (SARS-CoV-2), and it can raise the levels of albumin, lymphocytes, lymphocyte percentage, neutrophils, and CD8+ T cells, lower the levels of C-reactive protein and lactate dehydrogenase, and assist in the treatment of
10 infection with the novel coronavirus combined with lung damage and improve the recovery rate. The results of the clinical trial show that the traditional Chinese medicine composition according to the present disclosure is markedly efficacious in improving respiratory functions of subjects suffering lung damage after infection with the novel coronavirus (SARS-CoV-2), relieving their fatigue, and enhancing their exercise ability.